NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922
Luca Mologni(Azienda Ospedaliera San Gerardo), Carlo Gambacorti‐Passerini(Azienda Ospedaliera San Gerardo)
Cited by 33
Related Papers
Clinical and biological implications of driver mutations in myelodysplastic syndromes
|Blood|2013|1.8k
Somatic<i>SF3B1</i>Mutation in Myelodysplasia with Ring Sideroblasts
|New England Journal of Medicine|2011|1.2k
Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study
|The Lancet Haematology|2020|553
Bcr‐Abl stabilizes β‐catenin in chronic myeloid leukemia through its tyrosine phosphorylation
|The EMBO Journal|2007|214